Two pharma companies developing lipid-lowering drugs, MSD and Ionis, have reported positive phase 3 data that open the way for regulatory filings in the coming months. First up, MSD, which chalked up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback